Active — Not RecruitingNot Applicable

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

United States105 participantsStarted 2020-08-19

Plain-language summary

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Ability to provide informed consent
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Any of the following:
✓. Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.
✓. Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
✓. Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.

Place of death

Timeframe: At the time of death (for participants that die), assessed from enrollment through study completion, an average of 2 years

NCT IDNCT04482894

SponsorUniversity of Virginia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-05-09